Live /TUE 13 OCT 2026 /Seoul 05:11 KST /Issue No.367
Newsletter About Partnership Subscribe →
Section ArchiveTech · 680 stories
trendfeed
The Origin of Every Global Trend.
⌕ Search brands & keywords Get the feed
Hands On·Top List·The Brand·Community
RISING NOW
01 Meta Newsroom ▲1%02 NVIDIA News ▲0%03 Amazon Press Center (AWS) ▲0%04 CJ Newsroom ▲22%05 PROFILE ▲24%06 hot ▲0%07 Intel Newsroom ▲0%08 Alphabet Company Announcements ▲0%09 Samsung Global Newsroom ▲2%01 Meta Newsroom ▲1%02 NVIDIA News ▲0%03 Amazon Press Center (AWS) ▲0%04 CJ Newsroom ▲22%05 PROFILE ▲24%06 hot ▲0%07 Intel Newsroom ▲0%08 Alphabet Company Announcements ▲0%09 Samsung Global Newsroom ▲2%
Feed› Tech› The Brand 2026.02.27
Tech The Brand·5 min read·2026.02.27

엔비디아·릴리, AI 신약 개발 공동혁신 랩 출범

JIWOOTRENDFEED DESK

무슨 발표인가

  • 5년간 최대 $10억 투자 규모
  • 캘리포니아 베이에어리어 소재
  • 생물학·의학 전문가와 AI 엔지니어 협업

5년, 최대 10억 달러, 캘리포니아

원문 (영어)

News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery. The co-innovation lab infrastructure will be built on the NVIDIA BioNeMo platform and the NVIDIA Vera Rubin architecture.

NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and production. J.P. Morgan Healthcare Conference —NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.

The lab brings together Lilly’s world-leading expertise in discovering, developing and manufacturing medicines with NVIDIA’s leadership in AI, accelerated computing and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.

Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with top AI model builders and engineers from NVIDIA, allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development, using NVIDIA BioNeMo as the critical platform.

“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”

“For nearly 150 years, we’ve been working to bring life-changing medicines to patients,” said David A.

원문: NVIDIA News — "NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI" (2026-02-27) 공식 원문: https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai

© 2026 TrendFeed 무단전재 및 재배포 금지
→ READ NEXT All in Tech →
Food·5 MIN

CJ ENM, 베트남 극장가 15년 점유 — TOP5 중 3편 참여

Global·3 MIN

오프-화이트, 밀라노서 '10×10' 프로젝트 선보여

Global·2 MIN

로에베 2027 봄여름, 미국식 실용주의와 유희의 결합

← Previous엔비디아, Lumentum에 20억 달러 투자해 광학기술 협력 Next →노보 노디스크, 엔비디아와 AI 신약 개발 협력

바로가기 등록하시면, 더 쉽게 찾아보실 수 있습니다.